Multiple sclerosis, rituximab, and COVID-19.
Ann Clin Transl Neurol
; 8(4): 938-943, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1156855
ABSTRACT
We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4.81 million non-MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15-0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38-28.5, p = 0.0173) were independent predictors of COVID-19 severity. Rituximab-treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rituximab
/
COVID-19
/
Immunologic Factors
/
Multiple Sclerosis
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Ann Clin Transl Neurol
Year:
2021
Document Type:
Article
Affiliation country:
Acn3.51342
Similar
MEDLINE
...
LILACS
LIS